

PATENT APPLICATION  
U.S. Appln. No. 10/580,050  
International Application No. PCT/US04/39333  
Attorney Docket No. PP021454.0004(51835-US-PCT)

Express Mail Label No.: EM 407747575US      Date: July 1, 2009

**IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)**

In Re Application of: Qui-Lim Choo

U.S. Appln. No.: 10/580,050

Intl. Appln. No.: PCT/US04/39333

I.A. Filing Date: 11/19/2004

Priority Date: 11/19/2003

Title: METHODS AND REAGENTS FOR  
TREATING, PREVENTING AND  
DIAGNOSING *BUNYAVIRUS*  
INFECTION

Confirmation No.: 7391

Group Art Unit: To Be Assigned

Examiner: To Be Assigned

**RESPONSE TO NOTICE TO NOTICE OF ABANDONMENT**

Mail Stop PCT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In response to the "Notice of Abandonment" we are resubmitting a response to the "Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures", mailed February 18, 2009 from the United States Patent and Trademark Office(USPTO). The applicant would like to bring to the USPTO's attention multiple responses were submitted previous to this paper listed below. Copies of said papers are also provided herewith. Enclosed herewith are the following to complete the "Notice to

Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures" in the above-identified application:

1. COPY OF THE NOTICE OF ABANDONMENT
2. COPY OF NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES.
3. COPY OF THE PRELIMINARY AMENDMENT SUBMITTED JANUARY 31 2008 AND MARCH 20, 2009.
4. COPY OF PREVIOUSLY SUBMITTED TRANSMITTAL OF SEQUENCE LISTING INCLUDING:
  - a. Statements Under 37 C.F.R. 1.821(f-g), including statement specifically directing entry of the sequence listing into the application.
  - b. Paper Copy of the Sequence Listing (60 pages).
  - c. Copy Compact Disk Containing CRF Copy of Sequence Listing (1 CD).
5. COPY OF RETURN RECEIPT POSTCARDS DATED JANUARY 31, 2008 AND MARCH 20, 2008.

The Commissioner is hereby authorized to charge any deficiency in fees or credit any overpayment associated with this communication and which may be required under 37 C.F.R. §§ 1.16 and 1.17 to Deposit Account No. 03-1664.

Respectfully submitted,

NOVARTIS VACCINES AND DIAGNOSTICS, INC.

Dated: July 1, 2008

By: Regina Bautista  
Regina Bautista  
Registration No. 46,280

Customer No. 27476  
NOVARTIS VACCINES AND DIAGNOSTICS, INC.  
Corporate Intellectual Property – R338  
P.O. Box 8097  
Emeryville, CA 94662-8097  
Telephone: (510) 923-2192  
Facsimile: (510) 655-3542



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/580,050	Qui-Lim Choo	PP021454.0004

27476

NOVARTIS VACCINES AND DIAGNOSTICS INC.

INTELLECTUAL PROPERTY R338

P.O. BOX 8097

Emeryville, CA 94662-8097

INTERNATIONAL APPLICATION NO.

PCT/US04/39333

I.A. FILING DATE

11/19/2004


PRIORITY DATE

11/19/2003

CONFIRMATION NO. 7391

371

ABANDONMENT/TERMINATION  
LETTER



\*OC000000035945488\*

NOTIFICATION OF ABANDONMENT

Date Mailed: 05/14/2009

The United States Patent and Trademark Office in its capacity as a Designated / Elected Office (37 CFR 1.495) has made the following determination:

- The sequence requirements still haven't been met.

Therefore, the above identified application failed to meet the requirements of 35 U.S.C. 371 and 37 CFR 1.495, and is ABANDONED AS TO THE UNITED STATES OF AMERICA.

INDIA L EVANS

Telephone: (703) 756-1424

RSB 5/18/09 JX  
51835-US-PLA  
7/14/09

Submitted March 20, 2008  
(with copies of all documents submitted 1-31-2008)

SERIAL NO: 10/580,050 FILING DATE: 11-19-04 DKT NO: PP21454.0004  
TITLE: Method and Reagents for Treating preventing  
ATTY: RSB APPLICANT: Qui-Lim Choo DATE MAILED 3-20-09  
☐ CERTIFICATE OF MAILING ☒ EXPRESS MAIL LABEL NO: EM 028421462 US

THE U.S. PATENT & TRADEMARK OFFICE ACKNOWLEDGES RECEIPT OF:

- ☐ Auth. to Charge Deposit Account No. 03-4664 ☒ Certificate Under 37 C.F.R. §3.73(b)  
☐ Fee \$ \_\_\_\_\_ Check # \_\_\_\_\_ ☒ IDS with Form 1449 and \_\_\_\_\_ references  
☐ Provisional Application for Patent Cover Sheet ☒ Amendment Preliminary Amend  
☐ Utility Application Transmittal ☒ COPY Notice to File Missing Parts Application Filing Date Granted  
☐ Fee Transmittal Form / Fee Calculation Sheet ☒ Petition \_\_\_\_\_  
☐ \_\_\_\_\_ pp Spec. \_\_\_\_\_ pp Claims ☒ Request for Corrected Filing Receipt w/copy of Official Filing Receipt  
☐ Informal/Formal Drawings \_\_\_\_\_ sheets ☐ Notice of Appeal ☐ Issue Fee Transmittal B  
☐ Declaration \_\_\_\_\_ Signed \_\_\_\_\_ Unsigned ☐ Change of Correspondence Address  
☐ Application Data Sheet ☐ Transmittal Letter to the U.S. Designated/Elected (DO/EO/US) Concerning a Filing Under 35 USC 371  
☐ Paper Sequence Listing \_\_\_\_\_ Pages ☐ Copy of Notification of Missing Requirements under 35 U.S.C. 371 in the (DO/EO/US)  
☒ Disk Containing Sequence Listing # 1 copies ☐ PCT Request \_\_\_\_\_ Pages ☐ Demand (DC2)  
☐ Statement to Support Filing & Submission in Accordance with 37 CFR §§1.821 - 1.825 ☒ Response NT comply  
☐ Power of Attorney / Declaration and Power of Attorney ☐ \_\_\_\_\_  
☐ Assignment w/Recordation Cover Sheet \_\_\_\_\_ pages ☐ \_\_\_\_\_

51835- US-PCT



EM 028421462 US



UNITED STATES POSTAL SERVICE®

Customer Copy  
Label 11-F, April 2004

Post Office To Addressee

## ORIGIN (POSTAL SERVICE USE ONLY)

PO ZIP Code 94068	Day of Delivery <input checked="" type="checkbox"/> Next <input type="checkbox"/> 2nd <input type="checkbox"/> 2nd Del. Day	Postage \$ 17.50
Date Accepted 3/20/09	Scheduled Date of Delivery	Return Receipt Fee
Mo. Day Year	Month Day	\$
Time Accepted 1650	Scheduled Time of Delivery <input type="checkbox"/> Noon <input checked="" type="checkbox"/> 3 PM	COD Fee
<input type="checkbox"/> AM <input checked="" type="checkbox"/> PM	Military	\$
Flat Rate <input type="checkbox"/> or Weight 6 lbs. 0 ozs.	<input type="checkbox"/> 2nd Day <input type="checkbox"/> 3rd Day	Insurance Fee
	Int'l Alpha Country Code	\$ 7.10
	Acceptance Emp. Initials RJB	Total Postage & Fees
		\$

## DELIVERY (POSTAL USE ONLY)

Delivery Attempt	Time <input type="checkbox"/> AM <input type="checkbox"/> PM	Employee Signature
Mo. Day		
Delivery Attempt	Time <input type="checkbox"/> AM <input type="checkbox"/> PM	Employee Signature
Mo. Day		
Delivery Date	Time MAR 24 2009	Employee Signature
Mo. Day		
<input type="checkbox"/> WAIVER OF SIGNATURE REQUIRED - This service is void if waiver or addressee's signature is not present at time of delivery (location) and it authorizes that delivery employee's signature constitutes valid proof of delivery.		
NO DELIVERY	Weekend <input type="checkbox"/> Holiday <input type="checkbox"/>	Customer Signature

## CUSTOMER USE ONLY

## METHOD OF PAYMENT:

Express Mail Corporate Acct. No.

A940559

Federal Agency Acct. No. or  
Postal Service Acct. No.

FROM: (PLEASE PRINT)

PHONE ( )

ADVANTIS VACUUMS &  
DIAGNOSTICS INC.  
CORPORATE INTELLECTUAL  
PROPERTY #230  
PO BOX 2097  
EMERYVILLE

94068-0097

PP21454.0004 (51835-45-R24)

TO: (PLEASE PRINT)

PHONE ( )

MAIL STOP  
COMMISSIONER FOR PATENTS  
PO BOX 1000  
ALEXANDRIA

VA 22304-1000

FOR PICKUP OR TRACKING: Visit [www.usps.com](http://www.usps.com) or Call 1-800-222-1811



EM 028421462 US

Mail  
Label

UNITED STATES POSTAL SERVICE®

Post Office To Ad

ORIGIN (POSTAL SERVICE USE ONLY)			DELIVERY (POSTAL SERVICE USE ONLY)		
PO ZIP Code	Day of Delivery <input type="checkbox"/> Next <input type="checkbox"/> 2nd <input type="checkbox"/> 3rd Del. Day	Postage \$	Delivery Attempt	Time <input type="checkbox"/> AM <input type="checkbox"/> PM	Employee Signature
Date Accepted	Scheduled Date of Delivery Month Day	Return Receipt Fee \$	Mo. Day	Time <input type="checkbox"/> AM <input type="checkbox"/> PM	Employee Signature
Mo. Day Year	Scheduled Time of Delivery <input type="checkbox"/> Noon <input type="checkbox"/> 3 PM	COD Fee \$	Mo. Day	Time <input type="checkbox"/> AM <input type="checkbox"/> PM	Employee Signature
Time Accepted <input type="checkbox"/> AM <input type="checkbox"/> PM	Military <input type="checkbox"/> 2nd Day <input type="checkbox"/> 3rd Day	Insurance Fee \$	Delivery Date	Time <input type="checkbox"/> AM <input type="checkbox"/> PM	Employee Signature
Flat Rate <input type="checkbox"/> or Weight lbs. ozs.	Int'l Alpha Country Code	Total Postage & Fees \$	<input type="checkbox"/> WAIVER OF SIGNATURE (Domestic Mail Only) Additional merchandise insurance void if waiver of signature is requested. I wish delivery to be made without obtaining signature of addressee or addressee's agent (if delivery employee judges that article can be left in sect. location) and I authorize that delivery employee's signature constitutes valid proof of delivery.		
CUSTOMER USE ONLY			NO DELIVERY <input type="checkbox"/> Weekend <input type="checkbox"/> Holiday		
METHOD OF PAYMENT: Express Mail Corporate Acct. No. <b>X946559</b>			Customer Signature		
FROM: (PLEASE PRINT) PHONE ( )			TO: (PLEASE PRINT) PHONE ( )		
<b>NOVARTIS VACCINES &amp; DIAGNOSTICS INC</b> <b>CORPORATE INTELLECTUAL PROPERTY R338</b> <b>PO BOX 8097</b> <b>EMERYVILLE CA 94662-8097</b>			<b>MAIL STOP</b> <b>COMMISSIONER FOR PATENTS</b> <b>PO BOX 1450</b> <b>ALEXANDRIA VA 22313</b>		
<b>PP 21454,0004 (51835-US-FO)</b>					
FOR PICKUP OR TRACKING: Visit <b>www.usps.com</b> or Call 1-800-222-1811					
201/ 300 F:21 T:12					

SERIAL NO: 10/580,050 FILING DATE: 11-19-04 DKT NO: PP 21454,0004  
 TITLE: Method and Reagents for Treating preventing  
 ATTY: RSB APPLICANT: Qui-Lim Choo DATE MAILED: 3-20-09  
☐ CERTIFICATE OF MAILING ☒ EXPRESS MAIL LABEL NO: EM 028421462 US

## THE U.S. PATENT &amp; TRADEMARK OFFICE ACKNOWLEDGES RECEIPT OF:

- |   |  |
|---|--|
| <input type="checkbox"/> Auth. to Charge Deposit Account No. 03-1664  | <input type="checkbox"/> Certificate Under 37 C.F.R. §3.73(b)  |
| <input type="checkbox"/> Fee \$ _____ Check # _____   | <input type="checkbox"/> IDS with Form 1449 and _____ references   |
| <input type="checkbox"/> Provisional Application for Patent Cover Sheet                                     | <input checked="" type="checkbox"/> Amendment <u>Preliminary Amend</u>   |
| <input type="checkbox"/> Utility Application Transmittal  | <input type="checkbox"/> COPY Notice to File Missing Parts Application Filing Date Granted                                 |
| <input type="checkbox"/> Fee Transmittal Form / Fee Calculation Sheet                                       | <input type="checkbox"/> Petition _____  |
| <input type="checkbox"/> _____pp Spec. _____pp Claims _____pp Abstract                                      | <input type="checkbox"/> Request for Corrected Filing Receipt w/copy of Official Filing Receipt                            |
| <input type="checkbox"/> Informal/Formal Drawings _____ sheets  | <input type="checkbox"/> Notice of Appeal <input type="checkbox"/> Issue Fee Transmittal B                                 |
| <input type="checkbox"/> Declaration _____ Signed _____ Unsigned  | <input type="checkbox"/> Change of Correspondence Address  |
| <input type="checkbox"/> Application Data Sheet   | <input type="checkbox"/> Transmittal Letter to the U.S. Designated/Elected (DO/EO/US) Concerning a Filing Under 35 USC 371 |
| <input type="checkbox"/> Paper Sequence Listing _____ Pages   | <input type="checkbox"/> Copy of Notification of Missing Requirements under 35 U.S.C. 371 in the (DO/EO/US)                |
| <input checked="" type="checkbox"/> Disk Containing Sequence Listing # <u>1</u> copies                      | <input type="checkbox"/> PCT Request _____ Pages <input type="checkbox"/> Demand (DC2)                                     |
| <input type="checkbox"/> Statement to Support Filing & Submission in Accordance with 37 CFR §§1.821 - 1.825 | <input checked="" type="checkbox"/> Response <u>NT comply</u>  |
| <input type="checkbox"/> Power of Attorney / Declaration and Power of Attorney                              | <input type="checkbox"/> _____   |
| <input type="checkbox"/> Assignment w/Recordation Cover Sheet _____ pages                                   | <input type="checkbox"/> _____   |

PRESS HARD. YOU ARE MAKING 3 COPIES.

with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures" in the above-identified application:

1. **COPY OF** Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures.
2. **PRELIMINARY AMENDMENT.**
3. **TRANSMITTAL OF SEQUENCE LISTING INCLUDING:**
  - a. Statements Under 37 C.F.R. 1.821(f-g), including statement specifically directing entry of the sequence listing into the application.
  - b. Paper Copy of the Sequence Listing (60 pages).
  - c. Compact Disk Containing CRF Copy of Sequence Listing (1 CD).
4. **EXECUTED DECLARATIONS (6 PAGES).**
5. **RETURN RECEIPT POSTCARD.**

The Commissioner is hereby authorized to charge any deficiency in fees or credit any overpayment associated with this communication and which may be required under 37 C.F.R. §§ 1.16 and 1.17 to Deposit Account No. 03-1664.

Respectfully submitted,

NOVARTIS VACCINES AND DIAGNOSTICS, INC.

Dated: 3-17-09

By: Regina Bautista  
Regina Bautista  
Registration No. 46,280

Customer No. 27476

NOVARTIS VACCINES AND DIAGNOSTICS, INC.

Corporate Intellectual Property - R338

P.O. Box 8097

Emeryville, CA 94662-8097

Telephone: (510) 923-2192

Facsimile: (510) 655-3542




UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1350  
Alexandria, Virginia 22303-1450  
www.uspto.gov

U.S. APPLICATION NUMBER NO. 10/580,050	FIRST NAMED APPLICANT Qui-Lim Choo	ATTY. DOCKET NO. PP021454.0004
---	---------------------------------------	-----------------------------------

27476  
NOVARTIS VACCINES AND DIAGNOSTICS INC.  
INTELLECTUAL PROPERTY R338  
P.O. BOX 8097  
Emeryville, CA 94662-8097



INTERNATIONAL APPLICATION NO. PCT/US04/39333	
LA. FILING DATE 11/19/2004	PRIORITY DATE 11/19/2003

CONFIRMATION NO. 7391  
371 WITHDRAWAL NOTICE



Date Mailed: 02/18/2009

**Letter Regarding a New Notice and/or the Status of the Application**

If a new notice or Filing Receipt is enclosed, applicant may disregard the previous notice mailed on 01/16/2007. The time period for reply runs from the mail date of the new notice. Within the time period for reply, applicant is required to file a reply in compliance with the requirements set forth in the new notice to avoid abandonment of the application.

Registered users of EFS-Web may alternatively submit their reply to this notice via EFS-Web.  
<http://sportal.uspto.gov/authenticate/AuthenticateUserLocalEPF.html>

For more information about EFS-Web please call the USPTO Electronic Business Center at 1-866-217-9197 or visit our website at <http://www.uspto.gov/ebc>.

If the reply is not filed electronically via EFS-Web, the reply must be accompanied by a copy of the new notice.

If the Office previously granted a petition to withdraw the holding of abandonment or a petition to revive under 37 CFR 1.137, the status of the application has been returned to pending status.

INDIA L EVANS

Telephone: (703) 308-9140 EXT 212

RECEIVED 2/23/09  
FILED 51835 R.S. PCX  
DUE DATE 4/18/09  
Final D 11/15/09





UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

U.S. APPLICATION NUMBER NO. 10/580,050	FIRST NAMED APPLICANT Qui-Lim Choo	ATTY. DOCKET NO. PP021454.0004
---	---------------------------------------	-----------------------------------

27476  
NOVARTIS VACCINES AND DIAGNOSTICS INC.  
INTELLECTUAL PROPERTY R338  
P.O. BOX 8097  
Emeryville, CA 94662-8097

INTERNATIONAL APPLICATION NO. PCT/US04/39333	
LA. FILING DATE 11/19/2004	PRIORITY DATE 11/19/2003

**CONFIRMATION NO. 7391  
371 FORMALITIES LETTER**



Date Mailed: 02/18/2009

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT  
APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE  
AND/OR AMINO ACID SEQUENCE DISCLOSURES**

*Filing Date Granted*

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to comply with the sequence rules, 37 CFR §§ 1.821-1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR § 1.821(g). Extension of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR § 1.136. In no case may an applicant extend the period for response beyond the six-month statutory period. Direct the response to: Mail Stop Missing Parts, Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450.

- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

**For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:**

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ [ebc@uspto.gov](mailto:ebc@uspto.gov)

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

Registered users of EFS-Web may alternatively submit their reply to this notice via EFS-Web.  
<https://sportal.uspto.gov/authenticate/AuthenticateUserLocalEPF.html>

For more information about EFS-Web please call the USPTO Electronic Business Center at 1-866-217-9197 or visit our website at <http://www.uspto.gov/ebc>.

**If you are not using EFS-Web to submit your reply, you must include a copy of this notice.**

INDIA L EVANS

---

Telephone: (703) 308-9140 EXT 212



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/580,050	Qui-Lim Choo	PP021454.0004

27476  
NOVARTIS VACCINES AND DIAGNOSTICS INC.  
INTELLECTUAL PROPERTY R338  
P.O. BOX 8097  
Emeryville, CA 94662-8097

INTERNATIONAL APPLICATION NO.	
PCT/US04/39333	
I.A. FILING DATE	PRIORITY DATE
11/19/2004	11/19/2003

**CONFIRMATION NO. 7391**  
**371 FORMALITIES LETTER**



Date Mailed: 02/18/2009

## NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

*Filing Date Granted*

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to comply with the sequence rules, 37 CFR §§ 1.821-1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR § 1.821(g). Extension of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR § 1.136. In no case may an applicant extend the period for response beyond the six-month statutory period. Direct the response to: Mail Stop Missing Parts, Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450.

- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

**For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:**

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ [ebc@uspto.gov](mailto:ebc@uspto.gov)

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

Registered users of EFS-Web may alternatively submit their reply to this notice via EFS-Web.

<https://sportal.uspto.gov/authenticate/AuthenticateUserLocalEPF.html>



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/580,050	Qui-Lim Choo	PP021454.0004

27476

NOVARTIS VACCINES AND DIAGNOSTICS INC.

INTELLECTUAL PROPERTY R338

P.O. BOX 8097

Emeryville, CA 94662-8097

INTERNATIONAL APPLICATION NO.

PCT/US04/39333

I.A. FILING DATE


11/19/2004

PRIORITY DATE

11/19/2003

CONFIRMATION NO. 7391

371 WITHDRAWAL NOTICE



OC000000034583743

Date Mailed: 02/18/2009

**Letter Regarding a New Notice and/or the Status of the Application**

If a new notice or Filing Receipt is enclosed, applicant may disregard the previous notice mailed on 01/16/2007. The time period for reply runs from the mail date of the new notice. Within the time period for reply, applicant is required to file a reply in compliance with the requirements set forth in the new notice to avoid abandonment of the application.

Registered users of EFS-Web may alternatively submit their reply to this notice via EFS-Web.  
<https://sportal.uspto.gov/authenticate/AuthenticateUserLocalEPF.html>

For more information about EFS-Web please call the USPTO Electronic Business Center at 1-866-217-9197 or visit our website at <http://www.uspto.gov/ebc>.

If the reply is not filed electronically via EFS-Web, the reply must be accompanied by a copy of the new notice.

If the Office previously granted a petition to withdraw the holding of abandonment or a petition to revive under 37 CFR 1.137, the status of the application has been returned to pending status.

INDIA L EVANS

Telephone: (703) 308-9140 EXT 212

INDEXED and/or 2/23/09  
ALY RSB  
FILE 51835-43-PC  
Due Date  
Final Date 4/18/09  
PP021454 0004

Express Mail Label No.: ED 954551195 US      Date: January 31, 2008

**IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)**

In Re Application of: Qui-Lim Choo

U.S. Appln. No.: 10/580,050

Intl. Appln. No.: PCT/US04/39333

I.A. Filing Date: 11/19/2004

Priority Date: 11/19/2003

Title: METHODS AND REAGENTS FOR  
TREATING, PREVENTING AND  
DIAGNOSING *BUNYAVIRUS*  
INFECTION

Confirmation No.: 7391

Group Art Unit: To Be Assigned

Examiner: To Be Assigned

**TRANSMITTAL LETTER**

Mail Stop PCT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Enclosed herewith are the following documents to complete the above-identified application:


1. **TRANSMITTAL OF SEQUENCE LISTING INCLUDING:**
  - a. Statements Under 37 C.F.R. 1.821(f-g), including statement specifically directing entry of the sequence listing into the application.
  - b. Paper Copy of the Sequence Listing (60 pages).
  - c. Compact Disk Containing CRF Copy of Sequence Listing (1 CD).
2. **PRELIMINARY AMENDMENT.**
3. **RETURN RECEIPT POSTCARD.**

The Commissioner is hereby authorized to charge any deficiency in fees or credit any overpayment associated with this communication and which may be required under 37 C.F.R. §§ 1.16 and 1.17 to Deposit Account No. 03-1664.

Respectfully submitted,

NOVARTIS VACCINES AND DIAGNOSTICS, INC.

Dated: January 31, 2008

By:   
Helen Lee  
Registration No. 39,270

Customer No. 27476  
NOVARTIS VACCINES AND DIAGNOSTICS, INC.  
Corporate Intellectual Property – R338  
P.O. Box 8097  
Emeryville, CA 94662-8097  
Telephone: (510) 923-2192  
Facsimile: (510) 655-3542